The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Memory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories

Criteria

Inclusion Criteria:

• Clinical diagnosis of moderate to severe Alzheimer's disease;

• ambulatory patients

Exclusion Criteria:

• folate deficiency;

• clinically significant central nervous system disease other than Alzheimer's disease;

• clinically significant pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular disease